TY - JOUR
T1 - Current Transition Practice for Primary Immunodeficiencies and Autoinflammatory Diseases in Europe :
T2 - a RITA-ERN Survey
AU - Israni, Muskan
AU - Nicholson, Bethany
AU - Mahlaoui, Nizar
AU - Obici, Laura
AU - Rossi-Semerano, Linda
AU - Lachmann, Helen
AU - Hayward, Georgia
AU - Avramovič, Mojca Zajc
AU - Guffroy, Aurelien
AU - Dalm, Virgil
AU - Rimmer, Rachel
AU - Solis, Leire
AU - Villar, Carlotta
AU - Gennery, Andrew R.
AU - Skeffington, Stephanie
AU - Nordin, Julia
AU - Warnatz, Klaus
AU - Korganow, Anne-Sophie
AU - Antón, Jordi
AU - Cattalini, Marco
AU - Amin, Tania
AU - Berg, Stephan
AU - Soler-Palacín, Pere
AU - Burns, Siobhan O.
AU - Campbell, Mari
PY - 2022
Y1 - 2022
N2 - Due to the absence of curative treatments for inborn errors of immunity (IEI), children born with IEI require long-term follow-up for disease manifestations and related complications that occur over the lifespan. Effective transition from pediatric to adult services is known to significantly improve adherence to treatment and long-term outcomes. It is currently not known what transition services are available for young people with IEI in Europe. To understand the prevalence and practice of transition services in Europe for young people with IEI, encompassing both primary immunodeficiencies (PID) and systemic autoinflammatory disorders (AID). A survey was generated by the European Reference Network on immunodeficiency, autoinflammatory, and autoimmune diseases Transition Working Group and electronically circulated, through professional networks, to pediatric centers across Europe looking after children with IEI. Seventy-six responses were received from 52 centers, in 45 cities across 17 different countries. All services transitioned patients to adult services, mainly to specialist PID or AID centers, typically transferring up to ten patients to adult care each year. The transition process started at a median age of 16-18 years with transfer to the adult center occurring at a median age of 18-20 years. 75% of PID and 68% of AID centers held at least one joint appointment with pediatric and adult services prior to the transfer of care. Approximately 75% of PID and AID services reported having a defined transition process, but few centers reported national disease-specific transition guidelines to refer to. Transition services for children with IEI in Europe are available in many countries but lack standardized guidelines to promote best practice. The online version contains supplementary material available at 10.1007/s10875-022-01345-y.
AB - Due to the absence of curative treatments for inborn errors of immunity (IEI), children born with IEI require long-term follow-up for disease manifestations and related complications that occur over the lifespan. Effective transition from pediatric to adult services is known to significantly improve adherence to treatment and long-term outcomes. It is currently not known what transition services are available for young people with IEI in Europe. To understand the prevalence and practice of transition services in Europe for young people with IEI, encompassing both primary immunodeficiencies (PID) and systemic autoinflammatory disorders (AID). A survey was generated by the European Reference Network on immunodeficiency, autoinflammatory, and autoimmune diseases Transition Working Group and electronically circulated, through professional networks, to pediatric centers across Europe looking after children with IEI. Seventy-six responses were received from 52 centers, in 45 cities across 17 different countries. All services transitioned patients to adult services, mainly to specialist PID or AID centers, typically transferring up to ten patients to adult care each year. The transition process started at a median age of 16-18 years with transfer to the adult center occurring at a median age of 18-20 years. 75% of PID and 68% of AID centers held at least one joint appointment with pediatric and adult services prior to the transfer of care. Approximately 75% of PID and AID services reported having a defined transition process, but few centers reported national disease-specific transition guidelines to refer to. Transition services for children with IEI in Europe are available in many countries but lack standardized guidelines to promote best practice. The online version contains supplementary material available at 10.1007/s10875-022-01345-y.
KW - Transition
KW - Primary immunodeficiencies
KW - Autoinflammatory diseases
KW - Network
U2 - 10.1007/s10875-022-01345-y
DO - 10.1007/s10875-022-01345-y
M3 - Article
C2 - 36222999
SN - 0271-9142
VL - 43
SP - 206
EP - 216
JO - Journal of Clinical Immunology
JF - Journal of Clinical Immunology
ER -